[ad_1]
SpeeDx PlexPCR RespiVirus offers excellent sensitivity and improved productivity for a rapid and reproducible test of the respiratory virus.
SpeeDx Pty. Ltd. announced the submission of its PlexPCR® RespiVirus test to the Therapeutic Goods Administration (TGA). The company is planning a release in time for the 2019 flu season in Australia. The test uses the industry-leading PlexPCR® multiplex technology designed for the detection of 14 targets representing 10 viral pathogens responsible for respiratory diseases.
SpeeDx PlexPCR RespiVirus Detects Major Respiratory Pathogens, Including Influenza A, Influenza B, Rhinoviruses (A & B), Syncytial Respiratory Viruses (A & B), Human Metapneumoviruses, Adenoviruses, and Viruses 1, 2, 3 and 4.
The planned addition of RespiVirus PlexPCR will be added to SpeeDx's portfolio of infectious disease tests, which includes PlexPCR® VHS, a multiplex diagnostic test for herpes virus lesions (types 1 and -2); Varicella zoster virus, responsible for chickenpox and shingles; and Treponema pallidum, the bacterium responsible for syphilis. The other tests in the SpeeDx portfolio are specialized in badually transmitted infections (STIs) and genetic mutations related to antibiotic resistance.
[ad_2]
Source link
